Voting rights and capital

Hikma Pharmaceuticals Plc
02 April 2007




             Hikma Pharmaceuticals PLC - Voting Rights and Capital

LONDON, 2 April 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) notifies
the market that as at 31 March 2007 its capital consists of 169,137,407 ordinary
shares with voting rights. There are no shares held in treasury.

The above figure (169,137,407) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC
under the FSA's Disclosure and Transparency Rules.

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal                                     [phone]
Investor Relations Director

Brunswick Group

Jon Coles / Justine McIlroy / Alex Tweed               [phone]

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2006, the Group
had revenue of $317 million and profit attributable to shareholders of $54.5
million. For news and other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange